- Home
- PNI vs LENZ Comparison
PNI vs LENZ Comparison
Compare PNI & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | LENZ |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.2M | 142.0M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PNI | LENZ |
|---|---|---|
| Price | $6.17 | $3.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | 84.3K | ★ 666.8K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $153.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.08 | $3.60 |
| 52 Week High | $7.20 | $49.85 |
Technical Indicators
Market Signals| Indicator | PNI | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 22.32 | 33.95 |
| Support Level | N/A | $3.60 |
| Resistance Level | $7.10 | $6.11 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 23.08 | 23.38 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.